Complement-protected amphotropic retroviruses from murine packaging cells

Area of Science:

• Molecular Biology
• Gene Therapy
• Immunology

Background:

• Murine retroviruses are susceptible to inactivation by the human complement system, limiting their use in in vivo gene therapy.
• The human complement system poses a significant barrier to the efficacy of retroviral vectors in clinical applications.

Purpose of the Study:

• To engineer amphotropic retroviruses with enhanced resistance to human complement-mediated inactivation.
• To develop a novel fusion protein for improved retroviral vector stability in vivo.

Main Methods:

• Generated a fusion protein, DAFF2A, by combining the decay-accelerating factor (DAF) with the amphotropic murine leukemia virus (MuLV) 4070A envelope protein (EnvA).
• Expressed the DAFF2A fusion protein in NIH 3T3 helper cells and confirmed its presence and molecular weight via Western blot and antibody staining.
• Assessed viral titers and complement resistance of DAFF2A-modified retroviruses compared to wild-type.

Main Results:

• The DAFF2A fusion protein conferred significant protection against human complement attack on amphotropic retroviruses.
• DAFF2A-expressing retroviruses showed slightly reduced viral titers (1 x 10^5 CFU) compared to wild-type (5 x 10^5 CFU).
• Blocking the DAF domain of DAFF2A restored complement sensitivity, confirming the fusion protein's role in protection.

Conclusions:

• The DAFF2A fusion protein effectively shields retroviruses from human complement, overcoming a major hurdle in gene therapy.
• This novel approach offers a versatile tool for developing complement-resistant retroviral vectors for in vivo human gene therapy.
• The method's applicability across cell types suggests broad potential for advancing gene therapy applications.